Last updated on February 2018

Multicentre Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Brief description of study

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250109/L

Clinical Study Identifier: NCT03222843

Contact Investigators or Research Sites near you

Start Over

Yu Hu, Ph.D

Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, China
  Connect »

Ting Niu, MD

West China Hospital Sichuan University
Chengdu, China
  Connect »

Renchi Yang, MD

Hospital of Blood Diseases, Chinese Academy of Medical Sciences
Tianjin, China
  Connect »